Market News AIOpen the app

Eloxx Pharmaceuticals shared its third-quarter results and updates on its clinical trials.

ResultsRead the original at SEC EDGAR
Good for ELOX

Eloxx has begun its Alport study and cleared a second rare-kidney-disease study, advancing its drug tests. Neither study has reported results, and the second study will not start dosing until 2027.

ELOX · Eloxx Pharmaceuticals, Inc.

AI read · Good for ELOX

The AI's read

These steps let Eloxx test exaluren in 2 rare kidney diseases. An earlier study saw improved kidney structures in all 3 participants, but it was small. The current studies have not reported results, and the ADPKD study's first patient is not expected until the third quarter of 2027. Its main results are expected in 2029.

Get alerts for ELOX

Follow Eloxx Pharmaceuticals, Inc. (ELOX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ELOX
Free on the App Store and Google Play, or on the web.